
1. j antimicrob chemother. 2018 may 1;73(5):1158-1166. doi: 10.1093/jac/dkx529.

pathway involving n155h mutation hiv-1 integrase leads dolutegravir
resistance.

malet i(1)(2), ambrosio fa(3), subra f(4), herrmann b(4), leh h(4), bouger mc(4),
artese a(3), katlama c(5), talarico c(3), romeo i(3), alcaro s(3), costa g(3),
deprez e(4), calvez v(1)(2), marcelin ag(1)(2), delelis o(4).

author information: 
(1)sorbonne universités, upmc univ paris 06, inserm, institut pierre louis
d'epidémiologie et de santé publique (iplesp umrs 1136), 75013 paris, france.
(2)department virology, ap-hp, hôpital pitié-salpêtrière, paris, france.
(3)department health sciences, university "magna græcia" catanzaro, viale
europa, 88100 catanzaro, italy.
(4)lbpa, ens cachan, cnrs umr8113, ida fr3242, université paris-saclay, f-94235
cachan, france.
(5)department infectious diseases, hôpital pitié salpetriere, paris, france.

background: dolutegravir, integrase strand-transfer inhibitor (sti), shows a
high genetic barrier resistance. dolutegravir reported effective
against viruses resistant raltegravir elvitegravir. study, we
report case patient treated dolutegravir monotherapy. failure of
dolutegravir treatment observed concomitant appearance of
n155h-k211r-e212t mutations integrase (in) gene addition the
polymorphic k156n mutation present baseline patient.
methods: impact n155h-k156n-k211r-e212t mutations studied in
cell-free, culture-based assays molecular modelling.
results: cell-free culture-based assays confirm selected mutations in
the patient, context polymorphic mutation k156n present the
baseline, lead high resistance dolutegravir requiring analysis 
done timepoints longer usual properly reveal results.
interestingly, association n155h k156n sufficient for
significant resistance dolutegravir. modelling studies showed that
dolutegravir less stable in/dna complexes respect wt sequence.
conclusions: results indicate stability sti in/dna complexes is
an important parameter must taken account evaluating
dolutegravir resistance. study confirms pathway including n155h can
be selected patients treated dolutegravir help the
polymorphic k156n acts secondary mutation enhances resistance 
to dolutegravir.

doi: 10.1093/jac/dkx529 
pmid: 29373677  [indexed medline]

